The proposition has been put forward that activation of VDR may have the capacity to decrease the likelihood of acute respiratory distress syndrome (ARDS), cardiac complications, coagulopathy, and mortality in patients with COVID-1910–14. The gene discussed is VDR; the disease is acute respiratory distress syndrome.